Study of SPG302 in Adults With Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Schizophrenia
Interventions
DRUG

SPG302

small synthetic molecule

DRUG

Placebo

Placebo

Trial Locations (3)

3004

COMPLETED

Multidisciplinary Alfred Psychiatry Research Centre (MAPrc), Melbourne

3128

COMPLETED

Box Hill Hospital - Eastern Health, Box Hill

92845

RECRUITING

CenExel CNS, Garden Grove

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Spinogenix

INDUSTRY